Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Ermin as a biomarker for tracking brain myelin integrity in biofluids of patients with multiple sclerosis

FY 2023-24

Summary
Multiple sclerosis (MS) is a chronic, typically progressive brain disease involving damage to the protective sheaths covering nerve cells in the brain and spinal cord, myelin. It is one of the most common causes of neurological disability in young adults. The causes of MS are poorly understood, though components of autoimmune inflammation and an underlying degeneration of brain cells have been implicated in the disease. A major challenge in studying MS and similar conditions is the difficulty in measuring tissue damage and myelin changes without using expensive, inaccessible techniques like MRI. Development of a biomarker for myelin would be valuable for diagnostic, mechanistic, and therapeutic purposes. The goal of this project is to develop a blood test of myelin health. Ermin is specifically expressed in the myelin-producing cells that are attacked by the immune system and break down in MS. Changes in myelination are be expected to be paralleled by changes in Ermin levels. To investigate whether myelin damage correlates to changes in Ermin protein levels in the blood, I will first subject mice to a commonly used model of MS degeneration and examine immune cell alterations and brain tissue markers to assess the extent of myelin damage. Then, I will take fluids from these mice and develop a sensitive test that can track subtle changes in Ermin with the hypothesis that changes in Ermin protein levels from a healthy baseline will correlate to injury and MS-like symptoms in these mice. Successful development and validation of an Ermin detection assay will provide a crucial tool to evaluate disease state and response to treatment in MS and other disorders involving myelin pathology.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506518
Name
MacKeigan Tatiana P
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Ermin as a biomarker for tracking brain myelin integrity in biofluids of patients with multiple sclerosis
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Demyelination; Ermin; Multiple Sclerosis; Neurodegeneration; Oligodendrocytes
Abstract
Multiple sclerosis (MS) is a chronic, typically progressive brain disease involving damage to the protective sheaths covering nerve cells in the brain and spinal cord, myelin. It is one of the most common causes of neurological disability in young adults. The causes of MS are poorly understood, though components of autoimmune inflammation and an underlying degeneration of brain cells have been implicated in the disease. A major challenge in studying MS and similar conditions is the difficulty in measuring tissue damage and myelin changes without using expensive, inaccessible techniques like MRI. Development of a biomarker for myelin would be valuable for diagnostic, mechanistic, and therapeutic purposes. The goal of this project is to develop a blood test of myelin health. Ermin is specifically expressed in the myelin-producing cells that are attacked by the immune system and break down in MS. Changes in myelination are be expected to be paralleled by changes in Ermin levels. To investigate whether myelin damage correlates to changes in Ermin protein levels in the blood, I will first subject mice to a commonly used model of MS degeneration and examine immune cell alterations and brain tissue markers to assess the extent of myelin damage. Then, I will take fluids from these mice and develop a sensitive test that can track subtle changes in Ermin with the hypothesis that changes in Ermin protein levels from a healthy baseline will correlate to injury and MS-like symptoms in these mice. Successful development and validation of an Ermin detection assay will provide a crucial tool to evaluate disease state and response to treatment in MS and other disorders involving myelin pathology.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
MacKeigan, Tatiana P
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~